NurExone Biologic Inc. Opens the Market
05 Juli 2022 - 12:43PM
PR Newswire (Canada)
TORONTO, July 4, 2022
/CNW/ - Representatives from NurExone Biologic Inc. ("NurExone" or
the "Company") (TSXV: NRX) and their team joined Yossi Boker, TMX Head of Business Development,
Israel to celebrate the Company's
listing on TSX Venture Exchange and open the market.
NurExone is a pharmaceutical company developing a biological
extracellular vesicles (EV)-based technology drug platform. This is
a unique advanced treatment for reversing paralysis and improving
the quality of life of patients following spinal cord injury using
bio-guided exosomes (membrane-bound extracellular vesicles) loaded
with modified siRNA sequence.
For Market Openings: Media may pick up a feed from
the TOC (television operations centre) for all market open
ceremonies. The feed is named TSX Transmit 1 (SD-SDI) and is
produced at the TMX Broadcast Centre and sent live to the TOC. To
pick up the feed via the Dejero network, please contact
avservices@tmx.com. The client feature video will begin playing on
the TMX media wall at approximately 9:27
a.m. ET and the markets will open with the sound of a siren
at 9:30 a.m. ET
SOURCE TSX Venture Exchange
Copyright 2022 Canada NewsWire
Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024